Loading clinical trials...

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease | Clinical Trials | Clareo Health

TERMINATEDPhase 3NCT01127633

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

Lead sponsor: Eli Lilly and Company•64 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

RECRUITINGPhase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494 · Early Alzheimer's Disease

RECRUITINGPhase 2/3

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673 · Alzheimer's Disease Psychosis

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138 · Subjective Cognitive Decline (SCD), Functional Cognitive Disorder, and more

RECRUITINGPhase 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT07214727 · Alzheimer's Disease

RECRUITINGPhase 3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT07422857 · Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 8, 2019Terms

Trial snapshot

StatusTERMINATED

PhasePHASE3

Enrollment1,457

Start dateDec 2010

Last updatedOct 8, 2019

Condition

Alzheimer's Disease

Locations shown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Phoenix, Arizona

Sun City, Arizona

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2019Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions